Jian-Guo Zhou
周建国

jianguo.zhou@zmu.edu.cn
github.com/JianGuoZhou3
ORCID Scholar

Research summary

I am a Deputy Chief Physician (Master Thesis Supervisor) of Zunyi Medical University. My research focus on how to improve the efficacy and reduce the adverse effect of cancer immunotherapy and radiation/chemotherapy, etc.

Dr. Shixiang Wang and I leding a dynamic collaborative platform dedicated to advancing the frontier of cancer immunotherapy OncoHarmony-Network¹. Bringing together diverse teams from leading universities and research institutions, our network is committed to the exploration, mining, and integration of multi-omics data in the realm of cancer research. With a focus on fostering synergy among experts in the field, OncoHarmony Network aims to construct a comprehensive resource hub and cutting-edge tools for unraveling the complexities of tumor-immune interactions. Through collective knowledge and interdisciplinary collaboration, we strive to accelerate breakthroughs in the understanding and development of effective cancer therapies.

Research positions

year	what
2017	Primary Investigator, Department of Oncology, Second Affiliated hospital of Zunyi Medical University²

Medical positions

year	what
2024	Deputy Chief Physician, Master Thesis Supervisor, Oncology, Second Affiliated hospital of Zunyi Medical University](https://www.zy2yy.cn/)
2019	Attending Physician, Master Thesis Supervisor, Oncology, Second Affiliated hospital of Zunyi Medical University](https://www.zy2yy.cn/)
2017	Residency, Oncology, Second Affiliated hospital of Zunyi Medical University](https://www.zy2yy.cn/)

Education

year	what
2019	PhD in Radiation Oncology, University of Erlangen-Nuremberg³ Supervisor: [Prof. Udo Gaipl] (https://www.strahlenklinik.uk-erlangen.de)
2014	M.S. in Thoracic Oncology, Zunyi Medical University(https://www.zmu.edu.cn/) Supervisor: [Prof. Hu Ma] (https://www.zy2yy.cn/)
2009	M.D. in Clinical Medicine, Northwest Minzu University Supervisor: Prof. Siwu Fu

Major grants and funding

year	what
2024	Zunyi Medical University (ZYSE-2023-02)⁴ (¥ 2100k), Title: Future Science and Technology Elite Talent Cultivation Project
2021	[Lian Yun Gang Shi Hui Lan Public Foundation (Grant No. HL-HS2020-92)] (¥ 50k), Title: Based on machine learning methods to explore the role of multi-omics as predictor for NSCLC treated with third-generation EGFR-TKIs
2021	National Natural Science Foundation of China⁵ (¥ 340k), Title: Long noncoding RNA MALAT1 promotes Invasion and Metastasis via the FGF23 / β-catenin pathway-mediated EMT in Uterine Sarcoma
2019	Research Programs of Health Commission Foundation of Guizhou Province, gzwjkj2019-1-073⁶ (¥ 20k), Title: Identification and validation of Immune related Prognostic Models in Oral Squamous Cell Carcinoma
2018	the Special Key Laboratory of Oral Diseases Research, Higher Education Institution in Guizhou Province, No.05] (¥ 20k), Title: Identification and validation of a Prognostic Signature in Oral Cancer

Awards & honours

year	what
2022	Chinese Government Award for Outstanding Self-financed Students Abroad (2021-A404), Germany
	2021 Guizhou Medical Science and Techonology Award (Second Class, 1/6), Guizhou
2020	KSMO 2020 Young Investigator Award, Seoul
	2018 Guizhou Medical Science and Techonology Award (Third Class, 4/5), Guizhou
2019	ESMO Asia 2019 Merit Award, Singapore
	CSCO Young Oncologist Award (35 under 35), Beijing
2018	ESMO Asia 2018 Merit Award, Singapore

Publications

Journal articles (fully reviewed, # for co-first, † for corresponding)

year	number	citation
2024	J58	Effects of serial radon spa therapy on pain and peripheral immune status in patients suffering from musculoskeletal disorders– results from a prospective, randomized, placebo-controlled trial. A. Donaubauer^#, I. Becker, G. Klein, R. E. Voll, L. Weikl, M. Klieser, S. Barzangi, J. Zhou, R. Fietkau, U. S. Gaipl^†, B. Frey Frontiers in Immunology (JCR Q1, CAS Q2, IF: 7.3)
	J57	Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy J. Zhou^#, J. Yang^#, H. Wang, A. Hang-Heng Wong, F. Tan, X. Chen, s. he, G. Shen, Y. Wang, B. Frey, R. Fietkau, M. Hecht, W. Zhong, H. Ma^†, G. Udo^† BMJ Oncology
	J56	Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma - knowledge obtained from the CheckRad-CD8 trial M. Hecht^#†, B. Frey^#, U. S Gaipl^#, X. Tianyu, M. Eckstein, A. Donaubauer, G. Klautke, T. Illmer, M. Fleischmann, S. Laban, M. G Hautmann, B. Tamaskovics, T. B Brunner, I. Becker, J. Zhou, A. Hartmann, R. Fietkau, H. Iro, M. Döllinger, A. Gostian, A. M Kist Neoplasia (JCR Q2, CAS Q2, IF: 4.80)
	J55	TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy S. Wang^#, Y. Xiong^#, Y. Zhang^#, H. Wang, M. Chen, J. Li, P. Luo, Y. Luo, M. Hecht, B. Frey, U. Gaipl, X. Li^†, Q. Zhao^†, H. Ma^†, J. Zhou^† Journal for ImmunoTherapy of Cancer (JCR Q1, CAS Q1, IF: 10.9)
2023	J54	Identification of immunological bioprocesses involved in peri-implantitis using weighted gene co-expression network analysis L. Chen^#, S. Jin^#, Q. Lu, J. Zhou, J. Liu, X. Guan, H. Xia^†, H. He^† Journal of Periodontology (JCR Q1, CAS Q2 TOP, IF: 4.30)
	J53	Identification and characterization of circular RNAs as novel putative biomarkers to predict anti-PD-1 monotherapy response in metastatic melanoma patients - Knowledge from two independent international studies J. Zhou^#, R. Liang^#, H. Wang, S. Jin, W. Hu, B. Frey, R. Fietkau, M. Hecht, H. Ma^†, U. S Gaipl^† Neoplasia (JCR Q2, CAS Q2, IF: 4.80)
2022	J52	Identification of an endogenous retroviral signature to predict anti-PD1 response in advanced clear cell renal cell carcinoma: an integrated analysis of three clinical trials J. Zhou^#, Y. Zeng^#, H. Wang, S. Jin, Y. Wang, S. He, B. Frey, R. Fietkau, M. Hecht, H. Ma^†, W. Zhang^†, U. S Gaipl^† Therapeutic Advances in Medical Oncology (JCR Q2, CAS Q2, IF: 4.90)
	J51	Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials J. Zhou^#, A. Hang-Heng Wong^#, H. Wang^#, S. Jin, F. Tan, Y. Chen, S. He, G. Shen, B. Frey, R. Fietkau, M. Hecht, S. R Carr, R. Wang, B. Shen, D. S Schrump^†, H. Ma^†, U. S Gaipl^† Frontiers in Immunology (JCR Q1, CAS Q2 TOP, IF: 8.79)
	J50	Editorial: Uncovering Drug Resistance During Cancer Therapy H. Wang^†, R. Wang, J. Zhou, W. Hou, A. Hang-Heng Wong^† Frontiers in Genetics (JCR Q2, CAS Q3, IF: 3.70)
	J49	Elucidation of the Application of Blood Test Biomarkers to Predict Immune-Related Adverse Events in Atezolizumab-Treated NSCLC Patients Using Machine Learning Methods J. Zhou^†, A. Hang-Heng Wong^#, H. Wang, F. Tan, X. Chen, S. Jin, S. He, G. Shen, Y. Wang, B. Frey, R. Fietkau, M. Hecht, H. Ma^†, U. S Gaipl^† Frontiers in Immunology (JCR Q1, CAS Q2 TOP, IF: 8.79)
	J48	Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practic S. Ma^#, X. Bai^#, X. Guo ^#, L. Liu^#, L. Xiao, Y. Lin, J. Tan, X. Cai, Y. Wen, H. Ma, Q J. Fu, M. Leng, Y. Zhang, L. Long, Z. Guo, D. Wu^†, J. Zhou^†, Z. Dong^† BMC Medicine (JCR Q1, CAS Q1, IF: 11.81)
	J47	Editorial: The Clinical Application of Neoantigens J. Zhou^†, Z. Ding, H. Shi, M. Cheng Frontiers in Immunology (JCR Q1, CAS Q2 TOP, IF: 8.79)
	J46	Low-Dose Radiotherapy Leads to a Systemic Anti-Inflammatory Shift in the Pre-Clinical K/BxN Serum Transfer Model and Reduces Osteoarthritic Pain in Patients T. Weissmann^#, M. Rückert, J. Zhou, M. Seeling, S. Lettmaier, A. Donaubauer, F. Nimmerjahn, O. J Ott, M. Hecht, F. Putz, R. Fietkau, B. Frey, U. S Gaipl^†, L. Deloch Frontiers in Immunology (JCR Q1, CAS Q2 TOP, IF: 8.79)
2021	J45	Screening and validation of a novel T stage-lymph node ratio classification for operable colon cancer J. Pei^#, R. Zhang^#, N. Zhang^#, Y. Zeng, Z. Sun, S. Ma, J. Zhou, X. Li, J. Fan, J. Zhu, M. Abe, Z. Mei, G. Shi, C. Zhang^† Annals of Translational Medicine (JCR Q3, CAS Q4, IF: 3.62)
	J44	Establishment and Validation of a Prognostic Immune Signature in Neuroblastoma Y. Yu^#, Y. Zeng^#, X. Xia, J. Zhou, F. Cao^† Cancer Control (JCR Q3, CAS Q4, IF: 2.60)
	J43	Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy J. Zhou^#, B. Liang^#, J. Liu^#, S. Jin, S. He, B. Frey, N. Gu, R. Fietkau, M. Hecht, H. Ma^†, U. S Gaipl^† Cells (JCR Q2, CAS Q2, IF: 6.00)
	J42	Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer S. Semrau^†, A. Gostian, M. Traxdorf, M. Eckstein, S. Rutzner, J. von der Grün, T. Illmer, M. Hautmann, G. Klautke, S. Laban, T. Brunner, B. Tamaskovics, B. Frey, J. Zhou, C. Geppert, A. Hartmann, P. Balermpas, W. Budach, U. Gaipl, H. Iro, R. Fietkau, M. Hecht Cancers (Basel) (JCR Q2, CAS Q2, IF: 5.20)
	J41	Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors L. Maria Griewing^#, C. Schweizer, P. Schubert, S. Rutzner, M. Eckstein, B. Frey, M. Haderlein, T. Weissmann, S. Semrau, A. Gostian, S. K. Müller, M. Traxdorf, H. Iro, J. Zhou, U. S. Gaipl, R. Fietkau, M. Hecht^† BMC Cancer (JCR Q2, CAS Q2, IF: 3.80)
	J40	Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors J. Zhou^#, A. Donaubauer^#, B. Frey, I. Becker, S. Rutzner, M. Eckstein, R. Sun, H. Ma, P. Schubert, C. Schweizer, R. Fietkau, E. Deutsch, U. Gaipl^†, M. Hecht^† Journal for ImmunoTherapy of Cancer (JCR Q1, CAS Q1, IF: 13.75)
	J39	Editorial: The Role of ncRNAs in Solid Tumors Prognosis: From Laboratory to Clinical Utility J. Zhou^†, Z. Huang, O. Slaby, A. Navarro Frontiers in Oncology (JCR Q2, CAS Q2, IF: 5.74)
2020	J38	Development of an miRNA-Array-Based Diagnostic Signature for Periodontitis S. Jin^#, J. Zhou, X. Guan, G. Bai, J. Liu^†, L. Chen^† Frontiers in Genetics (JCR Q2, CAS Q3, IF: 3.70)
	J37	Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors P. Schubert^†, S. Rutzner, M. Eckstein, B. Frey, C. Schweizer, M. Haderlein, S. Lettmaier, S. Semrau, A. Gostian, J. Zhou, U. S Gaipl, R. Fietkau, M. Hecht Frontiers in Oncology (JCR Q2, CAS Q3, IF: 4.70)
	J36	Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy C. Schweizer^†, P. Schubert, S. Rutzner, M. Eckstein, M. Haderlein, S. Lettmaier, S. Semrau, A. Gostian, B. Frey, U. S Gaipl, J. Zhou, R. Fietkau, M. Hecht European Journal of Cancer (JCR Q1, CAS Q1, IF: 8.40)
	J35	Low Dose Radiation Therapy, Particularly with 0.5 Gy, Improves Pain in Degenerative Joint Disease of the Fingers: Results of a Retrospective Analysis A. Donaubauer^#, J. Zhou^#, O. J Ott, F. Putz, R. Fietkau, L. Keilholz, U. S Gaipl, B. Frey, T. Weissmann^† International Journal of Molecular Sciences (JCR Q1, CAS Q2, IF: 5.60)
	J34	Co-expression gene modules involved in cisplatin-induced peripheral neuropathy according to sensitivity, status, and severity R. Zhou^#, C. Chen^#, S. Jin, J. Li, Z. Xu, L. Ye^†, J. Zhou^† Journal of the Peripheral Nervous System (JCR Q2, CAS Q3, IF: 3.80)
	J33	Development and Validation of a Gene Signature for Prediction of Relapse in Stage I Testicular Germ Cell Tumors J. Zhou^#, J. Yang^#, S. Jin^#, S. Xiao, L. Shi, T. Zhang, H. Ma^†, U. S Gaipl^† Frontiers in Oncology (JCR Q2, CAS Q3, IF: 4.70)
	J32	Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials J. Zhou^#, L. Huang^#, S. Jin^#, C. Xu, B. Frey, H. Ma^†, U. S Gaipl^† ESMO Open (JCR Q1, CAS Q2, IF: 7.30)
2019	J31	Influence of marital status on overall survival in patients with ovarian serous carcinoma: finding from the surveillance epidemiology and end results (SEER) database P. Luo^#, J. Zhou^†, S. Jin, M. Qing, H. Ma^† Journal of Ovarian Research (JCR Q1, CAS Q3, IF: 4.00)
	J30	Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma J. Zhou^#, B. Liang^#, S. Jin^#, H. Liao, G. Du, L. Cheng, H. Ma^†, U. S Gaipl^† Frontiers in Oncology (JCR Q2, CAS Q3, IF: 4.70)
	J29	Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma J. Zhou^††, H. Zhao^#, S. Jin^#, X. Tian, H. Ma^† Gynecologic Oncology (JCR Q1, CAS Q2, IF: 4.70)
	J28	Identification of novel key lncRNAs involved in periodontitis by weighted gene co-expression network analysis S. Jin^#, R. Zhou^#, X. Guan^#, J. Zhou^†, J. Liu^† Journal of Periodontal Research (JCR Q2, CAS Q3, IF: 3.50)
	J27	An overview on the methodological and reporting quality of dose-response meta-analysis on cancer prevention C. Xu^#, Y. Liu, C. Zhang, J. S W Kwong, J. Zhou, L. Ge, J. Huang ^†, T. Liu ^† Journal of Cancer Research and Clinical Oncology (JCR Q2, CAS Q3, IF: 3.66)
	J26	Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma J. Zhou^#†, H. Zhong^#, J. Zhang, S. Jin, R. Roud, H. Ma^† Frontiers in Oncology (JCR Q2, CAS Q3, IF: 4.70)
2018	J25	Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial J. Zhou^#†, N. Zhou^#, Q. Zhang, Y. Feng, H. Zhou^† Trials (JCR Q3, CAS Q4, IF: 2.50)
	J24	Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention Z. Fathi^#, N. L Syn, J. Zhou, R. Roudi^† Journal of Human Genetics (JCR Q2, CAS Q3, IF: 3.55)
2017	J23	Opioid-Induced Constipation Relief From Fixed-Ratio Combination Prolonged-Release Oxycodone/Naloxone Compared With Oxycodone and Morphine for Chronic Nonmalignant Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials L. Huang^#, J. Zhou^#, Y. Zhang, F. Wang, Y. Wang, D. Liu, X. Li, S. Lv, S. Jin, Y. Bai, H. Ma^† Journal of Pain and Symptom Management (JCR Q1, CAS Q2, IF: 4.70)
	J22	Diagnostic accuracy of PCR for detecting ALK gene rearrangement in NSCLC patients: A systematic review and meta-analysis X. Zhang^#, J. Zhou^#, H. Wu, H. Ma^†, Z. Jiang^† Oncotarget (JCR Q2, CAS Q3, IF: 5.17)
	J21	Systematic review and meta-analysis of the efficacy of serum neuron-specific enolase for early small cell lung cancer screening L. Huang^#, J. Zhou^#, W. Yao^#, X. Tian, S. Lv, T. Zhang, S. Jin, Y. Bai and Hu Ma^† Oncotarget (JCR Q2, CAS Q3, IF: 5.17)
	J20	Concurrent chemo-radiotherapy with S-1 as an alternative therapy for elderly Chinese patients with non-metastatic esophageal squamous cancer: evidence based on a systematic review and meta-analysis G. Song^#, X. Tian^#, X. Liu^#, H. Chen, J. Zhou, W. Bian, W. Chen^† Oncotarget (JCR Q2, CAS Q3, IF: 5.17)
	J19	Meta-Analysis of Serum Gastrin-Releasing Peptide Precursor as a Biomarker for Diagnosis of Small Cell Lung Cancer S. Ping Lv^#, Y. Wang, L. Huang, F. Wang, J. Guo Zhou, H. Ma^† Asian Pacific Journal of Cancer Prevention
2016	J18	Meta-analysis comparing chewing gum versus standard postoperative care after colorectal resection G. Song^#, Y. Deng^#, Y. Jin^#, J. Zhou, X. Tian^† Oncotarget (JCR Q2, CAS Q3, IF: 5.17)
	J17	Efficacy of D5F3 IHC for detecting ALK gene rearrangement in NSCLC patients: a systematic review and meta-analysis H. Ma^#, W. Yao^#, L. Huang^#, S. Jin, D. Liu, Y. Liu, X. Tian, J. Tian, J. Zhou^† Oncotarget (JCR Q2, CAS Q3, IF: 5.17)
	J16	Laparoscopic cholecystectomy for acute cholecystitis: early or delayed?: Evidence from a systematic review of discordant meta-analyses G. Song^#, W. Bian^#, X. Zeng^#, J. Zhou, Y. Luo, X. Tian^† Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 1.60)
	J15	The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis W. Liu^#, J. Zhou, Y. Sun, L. Zhang, B. Xing^† Oncotarget (JCR Q2, CAS Q3, IF: 5.17)
	J14	The Adverse Events of Oxycodone in Cancer-Related Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials H. Ma^#, Y. Liu^#, L. Huang^#, X. Zeng, S. Jin, G. Yue, X. Tian, J. Zhou^† Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 1.60)
	J13	Moxibustion is an Alternative in Treating Knee Osteoarthritis: The Evidence From Systematic Review and Meta-Analysis G. Song^#, X. Tian^#, Y. Jin^#, Y. Deng, H. Zhang, X. Pang^†, J. Zhou^† Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 2.13)
2015	J12	The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis H. Ma^#, W. Yao^#, L. Huang^#, S. Jin, D. Liu, Y. Liu, X. Tian, J. Tian, J. Zhou^† Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 1.60)
	J11	Reply to comments on the relationship between green tea consumption and the risk of endometrial cancer Q. Zhou^#, H. Li, J. Zhou, T. Wu^† Archives of Gynecology and Obstetrics (JCR Q3, CAS Q3, IF: 2.60)
	J10	Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma: a Letter to Response W. Liu^#, J. Zhou, B. Xing^† Journal of Gastrointestinal Surgery (JCR Q2, CAS Q3, IF: 3.20)
	J09	Number of parity and the risk of gallbladder cancer: a systematic review and dose-response meta-analysis of observational studies P. Guo^†, C. Xu^#, Q. Zhou^#, J. Zhou, J. Zhao, Z. Si, C. Shen, C. Feng^† Archives of Gynecology and Obstetrics (JCR Q3, CAS Q3, IF: 2.60)
	J08	The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis J. Zhou^#, X. Tian^#, L. Cheng^#, Q. Zhou, Y. Liu, Y. Zhang, Y. Bai^†, H. Ma^† Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 1.60)
	J07	Coffee consumption and risk of endometrial cancer: a dose-response meta-analysis of prospective cohort studies Q. Zhou^#, M. Luo, H. Li, M. Li, J. Zhou^† scientific reports (JCR Q2, CAS Q2, IF: 5.23)
	J05	Role of Enteral Immunonutrition in Patients Undergoing Surgery for Gastric Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials G. Song^#, X. Tian^†, H. Liang^#, L. Yi^#, J. Zhou, Z. Zeng, T. Shuai, Y. Ou, L. Zhang, Y. Wang Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 1.60)
	J06	Oral Motor Intervention Improved the Oral Feeding in Preterm Infants: Evidence Based on a Meta-Analysis With Trial Sequential Analysis X. Tian^#, L. Yi^#, L. Zhang^#, J. Zhou, L. Ma, Y. Ou, T. Shuai, Z. Zeng, G. Song^† Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 1.60)
	J04	Immunonutrition Support for Patients Undergoing Surgery for Gastrointestinal Malignancy: Preoperative, Postoperative, or Perioperative? A Bayesian Network Meta-Analysis of Randomized Controlled Trials G. Song^#, X. Tian^†, L. Zhang^#, Y. Ou^#, L. Yi, T. Shuai, J. Zhou, Z. Zeng, H. Yang Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 1.60)
	J03	Green tea, black tea consumption and risk of endometrial cancer: a systematic review and meta-analysis Q. Zhou^#, H. Li^#, J. Zhou^#, Y. Ma, T. Wu^†, H. Ma^† Archives of Gynecology and Obstetrics (JCR Q3, CAS Q3, IF: 2.60)
	J02	Treatment of Adults With Treatment-Resistant Depression: Electroconvulsive Therapy Plus Antidepressant or Electroconvulsive Therapy Alone? Evidence From an Indirect Comparison Meta-Analysis G. Song^#, X. Tian^†, T. Shuai^#, L. Yi, Z. Zeng, S. Liu, J. Zhou, Y. Wang Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 1.60)
2014	J01	Treatment on advanced NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials J. Zhou^†, X. Tian^#, X. Wang^#, J. Tian, Y. Wang, F. Wang, Y. Zhang, H. Ma^† Medical Oncology (JCR Q3, CAS Q4, IF: 3.40)

The journal impact factors mentioned above are derived from the maximum values in the history of journal impact factors. Journal impact factors, Chinese Academy of Sciences (CAS) categorization, and JCR categorization were all uniformly updated on 2023.11.02. For future publications that are included, I will update them selectively and will no longer perform uniform updates on all publications.

Preprints (not reviewed, † for co-first, * for corresponding)

year	number	citation
2023	P1	FGF23 is a potential prognostic biomarker in uterine sarcoma L. Yang^#, Y. Cai^#, Y. Wang, Y. Huang, C. Zhang, H. Ma^†, J. Zhou^† NA

Cited by

Talks

year	number	what
2021	T5	ESMO Immuno-Oncology Congress 2021[Geneva, Switzerland] 3O - Identification of an endogenous retroviral signature to predict PD-1 blockade response in advanced clear cell renal cell carcinoma: Integrated analysis of 3 clinical trials
2020	T4	ESMO ASIA VIRTUAL CONGRESS 2020[Singapore, Republic of Singapore] Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors
	T3	KSMO 2020 VIRTUAL (13th Annual Meeting & 2020 International Conference; The Korean Society of Medical Oncology; 8th International FACO Conference) [SEOUL, KOREA] Identification of nine lncRNAs signature for predicting survival benefit of melanoma patients treated with immune checkpoint inhibitors
2019	T2	ESMO ASIA CONGRESS 2019[Singapore, Republic of Singapore] Olanzapine combined with 5-HT3 RA plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in cancer patients: A systematic review and meta-analysis of randomized controlled trials
	T1	EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY 2019 (14TH Meeting) [ LYON, FRANCE] Development and Validation of a RNA-Seq Based Prognostic Signature in Neuroblastoma

Poster presentations

year	number	what
2018	P3	ESMO Asia 2018 Congress 372P Identification and validation of a prognostic signature in malignant pleural mesothelioma
2023	P1	SITC 2023 189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy
	P2	SITC 2023 46 Efficacy of atezolizumab and docetaxel in patients with HER2-positive non-small cell lung cancer: a pooled post hoc of the OAK and POPLAR trials

Teaching experience

year	what
2022	International Academic Exchange, basic course for doctoral students, Zunyi Medical University
2022	Introduction to Clinical Research, Clinical Medicine Nanshan Class, Zunyi Medical University

Service

year	what
2023	Editorial Board Member of BMC Medicine
2023	Associate Editor of European Journal Of Medical Research
2022	Associate Editor of Frontiers in Immunology
2022	Associate Editor of Frontiers in Oncology
2022	Associate Editor Technology in Cancer Reasech & Treatment
2018	Journal Referees: Nature Medicine, Innovation, BMC Medicine, Seminars in Cancer Biology, cancer commnuications, Journal of Experimental & Clinical Cancer Research, Cell Proliferation, Frontiers in Immunology, Frontiers in OncologyGynecologic Oncology, iMeta, Strahlentherapie und Onkologie, Clinical and Translational Medicine, Nucleosides Nucleotides & Nucleic Acids, BMC Gastroenterology, Immunopharmacology And Immunotoxicology, Cancer Investigation, Oncoimmuology, Chinese Medical Journal, Journal of Cancer Research and Clinical Oncology, JCO Clinical Cancer Informatics, Ibrain, Journal of Proteome Research, Innovation Medicine, Genes & Diseases, Cancer Gene Therapy, Cellular Signaling, Molecular Oncology, Journal of Obstetrics and Gynaecology, Cancer Immunology Immunotherapy, Journal of the National Cancer Center, Journal for ImmunoTherapy of Cancer, Oncoimmunology, International Journal of Cancer, Clinical Nutrition, Computational and Structural Biotechnology Journal et al.
2018	Section Editor of Cancer Control
2022	Guest Editor of Therapeutic Advances in Med Oncol: Genomic Biomarkers in Cancer Immunotherapy

Jian-Guo Zhou 周建国